TWI924837B - 用於治療子宮漿液性癌之wee1化合物 - Google Patents
用於治療子宮漿液性癌之wee1化合物Info
- Publication number
- TWI924837B TWI924837B TW111113723A TW111113723A TWI924837B TW I924837 B TWI924837 B TW I924837B TW 111113723 A TW111113723 A TW 111113723A TW 111113723 A TW111113723 A TW 111113723A TW I924837 B TWI924837 B TW I924837B
- Authority
- TW
- Taiwan
- Prior art keywords
- administered
- therapeutically effective
- effective dose
- usc
- item
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/337—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having four-membered rings, e.g. taxol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/32—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163174004P | 2021-04-12 | 2021-04-12 | |
| US202163174005P | 2021-04-12 | 2021-04-12 | |
| US63/174,005 | 2021-04-12 | ||
| US63/174,004 | 2021-04-12 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| TW202304455A TW202304455A (zh) | 2023-02-01 |
| TWI924837B true TWI924837B (zh) | 2026-05-11 |
Family
ID=83640600
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TW111113723A TWI924837B (zh) | 2021-04-12 | 2022-04-11 | 用於治療子宮漿液性癌之wee1化合物 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20240197743A1 (cg-RX-API-DMAC7.html) |
| EP (1) | EP4322958A4 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2024517085A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2022259496A1 (cg-RX-API-DMAC7.html) |
| CA (1) | CA3213804A1 (cg-RX-API-DMAC7.html) |
| TW (1) | TWI924837B (cg-RX-API-DMAC7.html) |
| WO (1) | WO2022221143A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2021097139A1 (en) | 2019-11-15 | 2021-05-20 | Recurium Ip Holdings, Llc | Chiral synthesis of a tertiary alcohol |
| KR20230038523A (ko) | 2020-07-09 | 2023-03-20 | 리커리엄 아이피 홀딩스, 엘엘씨 | Wee1 억제제의 염 및 형태 |
| JP2024526203A (ja) * | 2021-06-23 | 2024-07-17 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Wee1阻害剤、及びがんを治療するための方法 |
| WO2024102650A1 (en) * | 2022-11-08 | 2024-05-16 | Zeno Management, Inc. | Intermittent dosing regimen for azenosertib in treating cancer |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112020018286A2 (pt) * | 2018-03-09 | 2020-12-29 | Recurium Ip Holdings, Llc | 1,2-di-hidro-3h-pirazolo[3,4-d]pirimidin-3-onas substituídas |
| WO2020069105A1 (en) | 2018-09-27 | 2020-04-02 | Dana-Farber Cancer Institute, Inc. | Degraders of wee1 kinase |
| WO2020210320A1 (en) * | 2019-04-11 | 2020-10-15 | Recurium Ip Holdings, Llc | Substituted l,2-dihydro-3h-pyrazolo[3,4-d]pyrimidin-3-ones |
-
2022
- 2022-04-08 EP EP22788687.6A patent/EP4322958A4/en active Pending
- 2022-04-08 US US18/554,951 patent/US20240197743A1/en active Pending
- 2022-04-08 WO PCT/US2022/024079 patent/WO2022221143A1/en not_active Ceased
- 2022-04-08 JP JP2023562607A patent/JP2024517085A/ja active Pending
- 2022-04-08 CA CA3213804A patent/CA3213804A1/en active Pending
- 2022-04-08 AU AU2022259496A patent/AU2022259496A1/en active Pending
- 2022-04-11 TW TW111113723A patent/TWI924837B/zh active
Non-Patent Citations (1)
| Title |
|---|
| 網路文獻 Zentalis, "Zentalis pharmaceuticals announces promising initial data presented in a late-breaking session at AACR on ZN-c3, its WEE1 inhibitor, in patients with advanced solid tumors" 2021/4/10 https://ir.zentalis.com/news-releases/news-release-details/zentalis-pharmaceuticals-announces-promising-initial-data/ |
Also Published As
| Publication number | Publication date |
|---|---|
| CA3213804A1 (en) | 2022-10-20 |
| EP4322958A1 (en) | 2024-02-21 |
| WO2022221143A1 (en) | 2022-10-20 |
| EP4322958A4 (en) | 2025-04-09 |
| TW202304455A (zh) | 2023-02-01 |
| JP2024517085A (ja) | 2024-04-19 |
| AU2022259496A1 (en) | 2023-10-12 |
| US20240197743A1 (en) | 2024-06-20 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102713072B1 (ko) | 두경부암 치료를 위한 egfr 저해제 | |
| TW202304455A (zh) | 用於治療子宮漿液性癌之wee1化合物 | |
| US20240197739A1 (en) | Combination Comprising Ribociclib and Amcenestrant | |
| EP4110326B1 (en) | Combination comprising alpelisib and 6-(2,4-dichlorophenyl)-5-[4-[(3s)-1-(3-fluoropropyl)pyrrolidin-3-yl]oxyphenyl]-8,9-dihydro-7h-benzo[7]annulene-2-carboxylic acid | |
| US20240335447A1 (en) | Wee1 inhibitor for cancer | |
| TW202333729A (zh) | 組合 | |
| CN118139625A (zh) | Wee1抑制剂和抗cd47抗体的组合 | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| US20250208149A1 (en) | Wee1 compound for treating uterine serous carcinoma | |
| US20250205240A1 (en) | Combinations | |
| JP2015007143A (ja) | 医薬組み合わせ | |
| EP4342475A1 (en) | Composition for treatment of covid-19 comprising taurodeoxycholic acid or pharmaceutically acceptable salt thereof as active ingredient | |
| CA2811345C (en) | Compound composition for inhalation used for treating asthma | |
| JP2021522345A (ja) | 新規なmct4阻害剤及びその使用 | |
| WO2021023291A1 (zh) | 原黄素在肺癌治疗中的应用 | |
| US20250161276A1 (en) | Drug combinations and methods of treating ovarian cancer | |
| CN120379657A (zh) | 用于治疗瘦素抵抗性肥胖的选择性下丘脑可渗透的hdac6抑制剂 | |
| TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
| CN117500505A (zh) | 用于治疗子宫浆液性癌的wee1化合物 | |
| JP2020536846A (ja) | Fgfr選択的チロシンキナーゼ阻害剤を含む医薬組成物 | |
| CN100455289C (zh) | 孟德拉明类抗癌药 | |
| CA2828296A1 (en) | Method for administration of a gamma secretase inhibitor | |
| TW202519221A (zh) | Wee1抑制劑及pkmyt1抑制劑之組合 | |
| HK40103578B (en) | Egfr inhibitor for the treatment of head and neck cancer | |
| CN114787151A (zh) | 喹唑啉衍生物或其盐、或其药物组合物的用途 |